Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic DiseaseNewsfile Corp • 07/05/23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201Newsfile Corp • 06/15/23
Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionNewsfile Corp • 06/06/23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public OfferingNewsfile Corp • 06/02/23
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease TreatmentsNewsfile Corp • 05/09/23
Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 MeetingNewsfile Corp • 05/01/23
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are BlindNewsfile Corp • 04/27/23
Kiora Pharmaceuticals' KIO-201 Heals Wounds in Phase 2 Trial of Patients with Persistent Corneal Epithelial DefectsNewsfile Corp • 04/26/23
Inherited Retinal Disease Expert, Mark Pennesi, M.D., Ph.D., Joins Kiora Pharmaceuticals' Scientific Advisory BoardNewsfile Corp • 04/21/23
Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune DiseasesNewsfile Corp • 04/17/23
Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 MeetingNewsfile Corp • 03/30/23
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development ProgressNewsfile Corp • 03/23/23
Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual MeetingNewsfile Corp • 03/10/23
Kiora's stock rallies as eye drop treatment moves into mid-stage clinical trialMarket Watch • 02/07/23
Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune DiseasesNewsfile Corp • 02/07/23
Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park CapitalNewsfile Corp • 02/03/23
Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company WebsiteNewsfile Corp • 01/09/23
Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023Newsfile Corp • 01/03/23
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A WarrantsNewsfile Corp • 11/18/22
Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis PigmentosaNewsfile Corp • 11/17/22
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's EndNewsfile Corp • 11/09/22